12:00 AM
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PEP02: Clinical trial started

Merrimack began a U.S. clinical trial to identify predictive biomarkers associated with MM-398 in about 12 patients with advanced colorectal, lung and triple-negative breast cancers. MM-398 is in the Phase III NAPOLI-1...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >